Blue chip battle: Cochlear v. ResMed

In a fierce head to head contest (well, fiercish), Cochlear wins on quality but ResMed trumps it for value.

The healthcare sector has been the source of two of Australia’s greatest success stories. Coincidentally both stocks initially listed in 1995 and, since then, Cochlear’s shares have increased twentyfold, while ResMed is up a remarkable 54 times.

In recent times, though, the gloss has come off, with both stocks losing favour with investors. Cochlear is now down 30% since it hit $82.87 in January last year, while ResMed has fallen 20% since peaking at $5.94 in October.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles